the republic logo

Anglo-Swedish pharmaceutical firm AstraZeneca predicts revenue decline as Crestor patent expires in the US


LONDON — Anglo-Swedish drug firm AstraZeneca says revenue will decline this year as it loses patent exclusivity in the United States on its top selling anti-cholesterol drug Crestor.

The company said Thursday that revenue and core earnings per share will decline by a "low to mid-single digit percentage" in 2016.

But CEO Pascal Soriot says the company has a strong pipeline of new drugs, particularly in cancer treatments.

He says the company is confident that strong strategic execution, combined with benefits from investments and new launches will keep it "on track to return to sustainable growth in line with our targets."

The comments came as AstraZeneca reported fourth quarter net income $808 million compared with a restated loss of $321 million in the same period a year earlier.

Think your friends should see this? Share it with them!

Story copyright 2016 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Feedback, Corrections and Other Requests: AP welcomes feedback and comments from readers. Send an email to and it will be forwarded to the appropriate editor or reporter.

We also have more stories about:
(click the phrases to see a list)


Follow The Republic:

All content copyright ©2016 The Republic, a publication of AIM Media Indiana unless otherwise noted.
All rights reserved. Privacy policy.